GlassScriptPhysician profile
Moutaz Sunbuli
NPI 1396963559
$6,875.32
in general payments reported to CMS, 2019-2025
32 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $423 · 2021: $655 · 2022: $1,134 · 2023: $1,309 · 2024: $1,192 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,620 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,620.11 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,677.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,000.89 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Jazz Pharmaceuticals INC. | $519.10 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $486.30 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.47 | 2019-2023 | Ofev |
| Inspire Medical Systems, INC. | $301.69 | 2021-2024 | Inspire |
| Electromed, INC. | $282.71 | 2019-2025 | Smartvest |
| Genzyme Corporation | $271.73 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $214.44 | 2019-2025 | Dupixent |
| Pulmonx Corporation | $211.78 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mallinckrodt Hospital Products INC. | $178.56 | 2022 | |
| Insmed, INC. | $166.53 | 2024-2025 | Arikayce, Brinsupri |
| Amgen INC. | $141.24 | 2022-2025 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $128.18 | 2023-2025 | Lumryz |
| Merck Sharp & Dohme LLC | $122.31 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $103.64 | 2019-2023 | Prolastin-C Liquid |
| United Therapeutics Corporation | $91.10 | 2024-2025 | Tyvaso, Tyvaso |
| Inogen, INC. | $90.42 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Genentech USA, INC. | $70.56 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $70.47 | 2022-2024 | Glassia |
| Teva Pharmaceuticals USA, INC. | $69.92 | 2021-2023 | Airduo Digihaler |
| Philips North America LLC | $48.23 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Mylan Specialty L.P. | $44.88 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.01 | 2020 | |
| Baxter Healthcare | $39.35 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Sunovion Pharmaceuticals INC. | $29.17 | 2019 | |
| Mallinckrodt Enterprises LLC | $26.74 | 2019 | |
| Verona Pharma, INC. | $26.15 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $19.82 | 2020 | |
| Scpharmaceuticals INC. | $19.38 | 2025 | |
| Pfizer INC. | $15.39 | 2025 | |
| Gilead Sciences, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moutaz Sunbuli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.